Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,257,085 papers from all fields of science
Search
Sign In
Create Free Account
Eloxatin
Known as:
Eloxatine
, Sanofi Synthelabo brand of oxaliplatin
, Sanofi brand of oxaliplatin
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
10 ML oxaliplatin 5 MG/ML Injection [Eloxatin]
Broader (1)
oxaliplatin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data
A. Kolbin
,
L. Namazova-Baranova
,
+4 authors
E. Dobrynina
2016
Corpus ID: 78542982
Background: Omalizumab is the first and yet the only biopreparation for asthma which combines high efficiency and high cost. The…
Expand
2011
2011
COMPARISON OF 5FU-BASE CHEMORADIATION WITH AND WITHOUT ELOXATIN ON PATHOLOGIC COMPLETE RESPONSE IN NEOADJUVANT CHEMO-RADIATION OF RECTAL CANCER
Y. Ali
,
A. Payam
,
M. Khosro
,
F. Mohammad
,
Shafaghi Behrouz
,
Davaei Manouchehr
2011
Corpus ID: 54757717
Background and Objectives: To compare pathologic complete response (PCR) in patients with advanced rectal cancer receiving…
Expand
2010
2010
Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer
M. Andersen
,
K. Schønnemann
,
M. Yilmaz
,
H. A. Jensen
,
L. Vestermark
,
P. Pfeiffer
Acta oncologica
2010
Corpus ID: 37011581
Abstract Background. ECF (epirubicin, cisplatin, 5-FU) has been a standard first-line regimen in patients with advanced gastro…
Expand
2006
2006
Comparative Cytotoxic Activity of Oxitan ® and Eloxatin ® in Colon Cancer Cell Line SW620
C. Hahnvajanawong
,
W. Tassaneeyakul
2006
Corpus ID: 78390182
Cytotoxic activities of a test formulation (Oxitan ® ) were compared to a reference formulation (Eloxatin ® ) against a colon…
Expand
2005
2005
Oxaliplatin (Eloxatin) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma.
E. Briasoulis
,
D. Rontogianni
,
V. Karavasilis
,
N. Pavlidis
Thyroid
2005
Corpus ID: 37608468
Therapeutic options for metastatic insular thyroid carcinoma (ITC) are very limited. We present the case of a 39-year-old woman…
Expand
2005
2005
Oxaliplatin activity in head and neck cancer cell lines
Magali Espinosa
,
Moises Martinez
,
+4 authors
J. Meléndez-Zajgla
Cancer Chemotherapy and Pharmacology
2005
Corpus ID: 595910
Oxaliplatin (cis-[(1R,2R)-1,2-cyclohexanediamine-N,N′] [oxalato(2-)-O,O′] platinum; Eloxatin) is a third-generation platinum…
Expand
2003
2003
Short-Time Infusion of Oxaliplatin (Eloxatin®) in Combination with Capecitabine (Xeloda®) in Patients with Advanced Colorectal Cancer
P. Pfeiffer
,
Pernille Hahn
,
Helle Anita Jensen
Acta oncologica
2003
Corpus ID: 25210534
Neuropathy exacerbated by exposure to cold is a dose-limiting toxicity of oxaliplatin. The incidence of this side effect is…
Expand
Review
2000
Review
2000
Novel combinations with oxaliplatin.
S. Mani
,
J. Manalo
,
D. Bregman
Oncology
2000
Corpus ID: 9830122
Oxaliplatin (Eloxatin) is a novel antineoplastic platinum derivative that may exert its cytotoxic effects by blocking DNA…
Expand
2000
2000
Oxaliplatin (Eloxatin): Fortschritte in der Tumortherapie 36th Annual Meeting of the American Society of Clinical Oncology (ASCO), New Orleans, May 2000
H. Schmoll
2000
Corpus ID: 79169823
Many people are trying to be smarter every day. How's about you? There are many ways to evoke this case you can find knowledge…
Expand
1998
1998
Targeting locoregional immunochemotherapy with new drugs in metastatic liver disease: a promising alternative.
N. Lygidakis
,
A. E. Berberabe
,
+4 authors
B. Sotiropoulou
Hepato-Gastroenterology
1998
Corpus ID: 19224518
BACKGROUND/AIMS A retrospective report of our experience with adjuvant targeted locoregional immunochemotherapy using new drugs…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE